Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed

HERON THERAPEUTICS, INC. /DE/

2026-Q1 EPS reported -$0.04 revenue$34,711,000

Total net revenue $34.7M vs $38.9M YoY; Acute Care franchise up 32% led by ZYNRELEF (+27%) and APONVIE (+50%).
Oncology net revenue $21.1M (-26.3% YoY) as CINVANTI declined 20.2% and SUSTOL wind-down continued.
Reaffirmed FY2026 guidance: net revenue $173-183M and Adjusted EBITDA $10-20M; cash $44.8M.
Settled CINVANTI patent litigation with Baxter; case dismissed April 28, 2026.
Sales force expansion on track for Q3 2026; ZYNRELEF prefilled syringe program on schedule with stability data in Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HERON THERAPEUTICS, INC. /DE/ reported the three months ended March 31, 2026 results: revenue $34.7 million. Guidance reaffirmed.

Period: the three months ended March 31, 2026
Revenue: $34.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

View on SEC.gov

Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-26-215752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.